The tumor kinetics of multiple myeloma following autologous stem cell transplantation as assessed by measuring serum-free light chains

Leukemia and Lymphoma

Volumn 47, Issue 1, 2006, Pages 21-28

  Pratt, Guy ^a,b   Mead, Graham P ^c   Godfrey, Keith R ^d   Hu, Ying ^d   Evans, Neil D ^d   Chappell, Michael J ^d   Lovell, Richard ^b   Bradwell, Arthur R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c Binding Site Group Ltd   (United Kingdom)

^d UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

Autologous peripheral blood stem cell transplant; Multiple myeloma; Serum free light chains

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN; PARAPROTEIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLOOD SAMPLING; CARCINOGENESIS; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; FOLLOW UP; HALF LIFE TIME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE; MALE; MULTIPLE MYELOMA; NEUTROPHIL; PRIORITY JOURNAL; PROGNOSIS; SENSITIVITY ANALYSIS;

ADULT; AGED; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM, RESIDUAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 30844456832     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190500254216     Document Type: Article

References (23)

1. Bradwell, A and Carr-Smith, H and Mead, G and Tang, L and Showell, P and Drayson, M and (2001) Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine Clin Chem, 47, pp. 73-680.
2. Bradwell, A and Carr-Smith, H and Mead, G. (2002) Serum free light chain immunoassays and their clinical application Clin App Immunol Rev, 3, pp. 17-33.
3. Drayson, M and Tang, L and Drew, R and Mead, G and Carr-Smith, H and Bradwell, A. (2001) Serum free light-chain measurements for identifying and monitoring patients with non-secretory multiple myeloma Blood, 97, pp. 2900-2902.
4. Katzmann, J and Clark, R and Abraham, R and Bradwell, A and Kyle, R and Gertz, M. (2002) Serum reference intervals and diagnostic ranges for free κ and free λ immunoglobulin light chains: Relative sensitivity for detection of monoclonal light chains Clin Chem, 48, pp. 1437-1444.
5. Marien, G and Oris, E and Bradwell, A and Blanckaert, N and Bossuyt, X. (2002) Detection of monoclonal proteins in sera by capillary zone electrophoresis and free light chain measurements Clin Chem, 48, pp. 1600-1601.
6. Bradwell, A and Carr-Smith, H and Mead, G and Harvey, T and Drayson, M. (2003) Serum test for assessment of patients with Bence Jones myeloma Lancet, 361, pp. 489-491.
7. Lachmann, H and Gallimore, R and Gillmore, J and Carr-Smith, H and Bradwell, A and Pepys, M and (2003) Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy Br J Haematol, 122, pp. 78-84.
8. UK Myeloma Forum. (2004) Guidelines on the diagnosis and monitoring of AL amyloidosis Br J Haematol, 125, pp. 881-700.
9. Mead, G and Carr-Smith, H and Drayson, M and Morgan, G and Child, J and Bradwell, A. (2004) Serum free light chains for monitoring multiple myeloma Br J Haematol, 126, pp. 348-354.
10. Tate, J and Mollee, P and Gill, D. (2005) Serum free light chains for monitoring multiple myeloma Br J Haematol, 128, pp. 405-406.
11. Tate, J and Gill, D and Cobcroft, R and Hickman, P. (2003) Practical considerations for the measurement of free light chains in serum Clin Chem, 49, pp. 1252-1257.
12. Rajkumar, S and Kyle, R and Therneau, T and Melton, L, III and Bradwell, A and Clark, R and (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance (MGUS) Blood, 106, pp. 812-817.
13. Junghans, R and Anderson, C. (1996) The protection receptor for IgG catabolism is the β2-microglobulin-containing neonatal intestinal transport receptor Proc Natl Acad Sci USA, 93, pp. 5512-5516.
14. Blade, J and Lopez-Guillermo, A and Bosch, F and Cervantes, F and Reverter, J and Montserrat, E and (1994) Impact of response to treatment on survival in multiple myeloma: Results in a series of 243 patients Br J Haematol, 88, pp. 117-121.
15. Durie, B and Jacobson, J and Barlogie, B and Crowley, J. (2004) Magnitude of response with myeloma frontline therapy does not predict out come: Importance of time to progression in southwest oncology group chemotherapy trials J Clin Onco, 22, pp. 1857-1863.
16. Schaar, C and Kluin-Nelemans, J and le Cessie, S and Franck, P and te Marvelde, M and Wijermans, P. (2004) Early response to therapy and survival in multiple myeloma Br J Haematol, 125, pp. 162-166.
17. Mazumdar, M and Bajorin, D and Bacik, J and Higgins, G and Motzer, R and Bosl, G. (2001) Predicting outcome to chemotherapy in patients with germ cell tumors: The value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy J Clin Oncol, 19, pp. 2534-2541.
18. See, W and Cohen, M and Hoxie, L. (1993) Alpha-fetoprotein half-life as a predictor of residual testicular tumor effect of the analytic strategy on test sensitivity and specificity Cancer, 71, pp. 2048-2054.
19. Attal, M and Harousseau, J and Facon, T and Guilhot, F and Doyen, C and Fuzibet, J and (2003) Single versus double autologous stem cell transplantation for multiple myeloma N Engl J Med, 349, pp. 2495-2502.
20. Porrata, L and Gertz, M and Inwards, D and Litzow, M and Lacy, M and Tefferi, A and (2001) Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma Blood, 98, pp. 579-585.
21. Barlogie, B and Shaughnessy, J and Tricot, G and Jacobson, J and Zangari, M and Anaissie, E and (2004) Treatment of multiple myeloma Blood, 103, pp. 20-32.
22. Davies, F and Forsyth, P and Rawstron, A and Owen, R and Pratt, G and Evans, P and (2001) The impact of attaining a minimal disease state after high dose melphalan and autologous transplantation for multiple myeloma Br J Haematol, 112, pp. 814-819.
23. Savage, D and Mears, J and Balmaceda, C and Rescigno, J and Shendrik, I and Mansukhani, M and (2002) Leptomeningeal relapse of multiple myeloma following allogeneic stem cell transplantation Leuk Res, 26, pp. 689-692.